In a Reversal, F.D.A. Calls for Limits on Who Gets Alzheimer’s Drug

https://ift.tt/wEcZxH agency faced criticism for approving Aduhelm for all Alzheimer’s patients. The new label recommends that the drug be given only to patients with mild symptoms.

from NYT > Top Stories https://ift.tt/3jYfLZ8